We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


This Week on NeuroScientistNews: 9 March – 13 March

This Week on NeuroScientistNews: 9 March – 13 March content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Friday the 13th; combination treatment for addiction; genetic biomarkers for autism, and more.

What the science says about Friday the 13th

For some people, Friday the 13th instills fear and dread, while for others it’s just another Friday. But does science support the superstitions behind this apprehension? Should you get out of bed today or tuck yourself back under the covers to stay safe and sound? Over the years, scientists have analyzed the data, dissecting the underlying accident rates of this proposed unlucky day.

Remediation of addiction with a 1-2 punch of DBS & dopamine receptor antagonists

Pathological changes to synaptic transmission underlie part of the etiology of different neurological and psychiatric diseases including Parkinson’s disease and drug addiction. Deep brain stimulation (DBS) is an effective treatment for tremors associated with Parkinson’s disease. In a recent article published in Science, Creed, Pascoli and Lüscher demonstrate that a combination of DBS and pharmaceuticals leads to long-term improvement in synaptic transmission and addiction-related behavior.

Blood-based genetic biomarkers identify young boys with autism

In a study published in JAMA Psychiatry, an international team of scientists report finding a highly accurate blood-based measure that could lead to development of a clinical test for autism spectrum disorder (ASD) risk in males as young as one to two years old. The test could be done in community pediatric settings. The degree of accuracy, they said, out performs other behavioral and genetic screens for infants and toddlers with ASD described in literature.

Promising Alzheimer’s treatment moves toward clinical trials

A promising new natural treatment for Alzheimer's disease is moving toward clinical trials. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer's. Muraleedharan Nair, Michigan State University natural products chemist, has patented a botanical compound, withanamides. His spinoff company, Natural Therapeutics, will begin the trials as soon as funding is in place.

Meta-study shows that the experience of time is altered in depression

Time perception is highly subjective and usually depends on the relevant situation so that, for instance, your sense of how fast or slow time is passing can be influenced by whether you are waiting for something or if a deadline is approaching. Patients suffering from depression appear to experience time differently than healthy individuals. Statements made by corresponding patients indicate that for them time seems to pass extremely slowly or even stands still.